Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | DUSP10 | Q9Y6W6 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6799646 | 0.63 | KDM4E (0.60) | KDM4EALDH1A1POLBRXFP1LRRK2 | |
| SCHEMBL31435609 | 0.63 | CYP11B2 (0.37) | ALDH1A1LMNA | |
| SCHEMBL7593726 | 0.63 | KDM4E (0.42) | KDM4EALDH1A1POLBRXFP1LRRK2 | |
| SCHEMBL6800532 | 0.62 | GABRG2 (0.65) | KDM4EALDH1A1POLBRXFP1LRRK2 | |
| SCHEMBL23111604 | 0.61 | LRRK2 (0.60) | KDM4EALDH1A1POLBRXFP1LRRK2 | |
| SCHEMBL2040799 | 0.60 | BRD4 (0.36) | KDM4EALDH1A1POLBRXFP1MAPT | |
| SCHEMBL15329160 | 0.60 | TSHR (0.47) | CYP2A6MAOAMAOB | |
| SCHEMBL2434846 | 0.60 | ALDH1A1 (0.56) | KDM4EALDH1A1POLBRXFP1LRRK2 | |
| SCHEMBL1060812 | 0.60 | KDM4E (1.00) | KDM4EALDH1A1POLBRXFP1LRRK2 | |
| SCHEMBL6196968 | 0.58 | MEN1 (0.31) | ALDH1A1MEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2001503408-A | — | — | 2001-03-13 | — | — | JP | claimed |
| EP-0937072-A1 | THIENYLCYCLOHEXANONE DERIVATIVES AS LIGANDS OF THE GABA A? $g(a)5 RECEPTOR SUBTYPE | MERCK SHARP & DOHME LTD. (GB) | 1999-08-25 | — | — | EP | claimed |
| WO-1998018792-A1 | THIENYLCYCLOHEXANONE DERIVATIVES AS LIGANDS OF THE GABAA α5 RECEPTOR SUBTYPE | MERCK SHARP & DOHME LIMITED (GB) | 1998-05-07 | — | — | WO | claimed |
| US-20230181588-A1 | Compounds and Compositions for Treating Fibrosis | UNIV YALE (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230181588-A1 | Compounds and Compositions for Treating Fibrosis | UNIV YALE (US) | 2023-06-15 | — | — | US | disclosed |
| US-11613526-B2 | Thiophene derivatives | MERCK PATENT GMBH (DE) | 2023-03-28 | — | — | US | disclosed |
| US-11613526-B2 | Thiophene derivatives | MERCK PATENT GMBH (DE) | 2023-03-28 | — | — | US | disclosed |
| US-11504373-B2 | Compounds and compositions for treating fibrosis | YALE UNIVERSITY (US) | 2022-11-22 | — | — | US | disclosed |
| US-20210198233-A1 | Thiophene derivatives | MERCK PATENT GMBH (DE) | 2021-07-01 | — | — | US | disclosed |
| US-20210198233-A1 | Thiophene derivatives | MERCK PATENT GMBH (DE) | 2021-07-01 | — | — | US | disclosed |
| EP-3793989-A1 | THIOPHENE DERIVATIVES | Merck Patent GmbH (DE) | 2021-03-24 | — | — | EP | disclosed |
| CN-112313211-A | Thiophene derivatives | 默克专利股份公司 | 2021-02-02 | — | — | CN | disclosed |
| US-20200390770-A1 | Compounds and Compositions for Treating Fibrosis | UNIV YALE (US) | 2020-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11504373-B2 | Compounds and compositions for treating fibrosis | DUSP5, DUSP15, LPCAT3 | KDM4E 631/4885ALDH1A1 1246/4885POLB 4165/4885 |
| US-20210198233-A1 | Thiophene derivatives | HIF1A, HIF1AN, NCOA1 | KDM4E 2461/4885ALDH1A1 240/4885POLB 1800/4885 |
| US-11613526-B2 | Thiophene derivatives | HIF1A, HIF1AN, NCOA1 | KDM4E 2461/4885ALDH1A1 240/4885POLB 1800/4885 |
| US-20230181588-A1 | Compounds and Compositions for Treating Fibrosis | DUSP5, DUSP15, DUSP26 | KDM4E 349/4885ALDH1A1 1636/4885POLB 3997/4885 |
| US-20200390770-A1 | Compounds and Compositions for Treating Fibrosis | DUSP5, DUSP15, LPCAT3 | KDM4E 631/4885ALDH1A1 1246/4885POLB 4165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.